|
|
Other links at Articles > Hematology-Oncology |
| 1. |
Ponatinib: The Real Deal for Refractory CML?
|
|
|
Dr. Jorge Cortes reports the results of his study of ponatinib, a promising new third-generation TKI active against refractory CML, and updates Bruce Cheson on other important CML abstracts from ASH. Medscape Hematology-Oncology
|
|
|